FDA guides on the next Ph 2 study for advancement of Next Generation Capecitabine (“NGC-Cap”) for cancer patients
“The FDA provided helpful guidance on the overall design of our NGC-Cap Phase 2 study for which we anticipate beginning enrollment in mid-2024. We believe that NGC-Cap may provide a better safety/efficacy profile than FDA-approved Capecitabine, eventually providing treatment for the tens of thousands of patients who cannot tolerate the existing Capecitabine,” said David Young, PharmD, Ph.D, President of Research and Development at Processa. “The results to date of our present Phase 1b oncology study clearly show that the metabolism and distribution of NGC-Cap is better than Capecitabine and that the safety/efficacy profile will likely be significantly better once we can identify the optimal dosage regimen.”
Share:
More News
Søren Bregenholt, CEO of Alligator Bioscience, commented: “The orphan designation to HLX22 in Europe represents another important regulatory milestone for this program. Following the earlier FDA designation, this reinforces the potential clinical and commercial value of the antibody. While Alligator is not directly involved in the development, we look forward
Abbisko Therapeutics announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib, has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of Hepatocellular Carcinoma (HCC). Irpagratinib is the first therapeutic agent to leverage
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are very pleased that the NDA application for the fourth indication of our core product, sac-TMT, has been accepted by the CDE of NMPA, which is another breakthrough for the breast cancer treatment field. This not only verifies the clinical value and
“The clearance of our IND for AVZO-1418 is a significant achievement for Avenzo as this is our second IND in 3 weeks to receive clearance and our first ADC program to advance into the clinic,” said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. “We believe AVZO-1418
